Similar articles

• [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].

  Silber S, Helms TM, Garlichs C, Arntz HR, Weil J, Ince H, Klingenheben T, Hoffmann S, Boudriot E, Steiger H, Zugck C. Silber S, et al. Dtsch Med Wochenschr. 2011 Apr;136(15):782-5. doi: 10.1055/s-0031-1272567. Epub 2011 Mar 22. Dtsch Med Wochenschr. 2011. PMID: 21432747 Review. German. No abstract available.
• Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.

  Lyseng-Williamson KA. Lyseng-Williamson KA. Am J Cardiovasc Drugs. 2012 Jun 1;12(3):207-16. doi: 10.2165/11209640-000000000-00000. Am J Cardiovasc Drugs. 2012. PMID: 22583148
• Current oral antiplatelets: focus update on prasugrel.

  John J, Koshy SK. John J, et al. J Am Board Fam Med. 2012 May-Jun;25(3):343-9. doi: 10.3122/jabfm.2012.03.100270. J Am Board Fam Med. 2012. PMID: 22570398 Review.
• Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors.

  Ogawa H, Hokimoto S, Kaikita K, Yamamoto K, Chitose T, Ono T, Tsujita K. Ogawa H, et al. J Cardiol. 2011 Jul;58(1):6-17. doi: 10.1016/j.jjcc.2011.03.002. Epub 2011 Apr 29. J Cardiol. 2011. PMID: 21530174 Review.
• Triple therapy: boon or bane for high-risk CV patients?

  Phillippe HM, Baty SR, Griffith CB. Phillippe HM, et al. J Fam Pract. 2011 Apr;60(4):187-92. J Fam Pract. 2011. PMID: 21472149 Review.